Peijia Medical Limited (HKG:9996)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 3.24B -23.2% |
| Revenue (ttm) | 905.10M +17.4% |
| Net Income | -162.77M |
| EPS | -0.24 |
| Shares Out | 672.63M |
| PE Ratio | n/a |
| Forward PE | 582.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 207,000 |
| Open | 4.810 |
| Previous Close | 4.810 |
| Day's Range | 4.625 - 4.850 |
| 52-Week Range | 3.730 - 7.370 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 9.81 (+103.95%) |
| Est. Earnings | Nov 20, 2026 |
About Peijia Medical
Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People’s Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve s... [Read more]
Financial Performance
In 2025, Peijia Medical's revenue was 712.87 million, an increase of 15.82% compared to the previous year's 615.48 million. Losses were -203.29 million, -10.28% less than in 2024.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for 9996 stock is "Strong Buy." The 12-month stock price target is $9.81, which is an increase of 103.95% from the latest price.
News
Peijia Medical Announces 2025 Annual Results
SUZHOU, China, March 26, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, ...
DCwire® Micro Guidewire Receives FDA 510(k) Clearance, Marking a Key Milestone in Peijia Medical's Global Expansion
SUZHOU, China, March 18, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, ...
Peijia Medical Submits EU MDR CE Mark Registration Application for GeminiOne® TEER System
HONG KONG, Feb. 9, 2026 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration ap...
Peijia Medical Receives NMPA Approval for TaurusTrio Transcatheter Aortic Valve System, Pioneering Treatment for Aortic Regurgitation in China
HONG KONG , Dec. 12, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, anno...
Peijia Medical Announces 2025 Interim Results
HONG KONG , Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, annou...
Peijia Medical Announces 2024 Annual Results
HONG KONG , March 26, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, anno...
Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical
SUZHOU, China , Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, ...